Suven Life Sciences announced that they secured patents in Australia, Canada, Japan and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action - H3 Inverse agonist.

These patents are valid until 2030. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders.

Venkat Jasti, chief executive officer, Suven Life Sciences said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and huge market potential globally."

Shares of the company gained Rs 4.5, or 1.89%, to settle at Rs 242.80. The total volume of shares traded was 232,211 at the BSE (Monday).